General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Lucentis Information Center

Last Updated February 5, 2015

Lucentis is approved in 5 indications: wet age-related macular degeneration (wet AMD), visual impairment due to diabetic macular edema (DME) and due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO); and visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).

Lucentis’ safety profile has been well established in an extensive clinical development program that enrolled more than 12,500 patients. Additionally, to demonstrate the benefits and safety profile of Lucentis in the real world setting, Novartis launched the LUMINOUS program. LUMINOUS is the largest observational study in ophthalmology with more than 30,000 patients enrolled worldwide.

To improve the unmet medical needs in eye care in developing countries, Novartis Pharmaceuticals and Alcon have sponsored the eXcellence in Ophthalmology Vision Award (XOVA) award program since 2010. The objective of XOVA is to provide funding to medical specialists, in the form of a grant, for non-profit initiatives that are expected to have a positive impact on improving the quality of eye care and addressing unmet medical needs. In the last 5 years, projects in 16 developing countries have been supported.